secwatch.observer — SEC 8-K summary
======================================

Issuer:     PharmaCyte Biotech, Inc. (PMCB)
CIK:        0001157075
Form:       8-K
Filed at:   2022-07-21T23:59:59+00:00
Accession:  0001683168-22-005063
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PharmaCyte Biotech commences pilot phase of pig study to address FDA clinical hold for pancreatic cancer trial
--------------------------------------------------------------------------------

- Pilot study in two Yorkshire pigs evaluates microcatheter delivery of CypCaps into pancreatic arterial system.
- Data will finalize full-scale 90-pig study protocol; results to be presented to FDA in Type A meeting.
- Study aims to lift clinical hold on planned Phase 2b trial for locally advanced inoperable pancreatic cancer (LAPC).
- CypCaps contain radiopaque microspheres to track movement via imaging and histology over one-week observation.
- Study conducted by CBSET, Inc. in Lexington, MA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1157075/000168316822005063/0001683168-22-005063-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1157075/000168316822005063/pharmacyte_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-22-005063

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer